Related Experiment Video

Updated: Jun 4, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae

Shipeng Sun1, Wenli Li, Yu Sun

  • 1Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.

Biochemical and Biophysical Research Communications
|March 3, 2011
PubMed

Insights

Messenger RNA (mRNA) vaccines offer a safer alternative to DNA vaccines. Researchers developed a novel MS2 bacteriophage virus-like particle (VLP) delivery system for mRNA vaccines, demonstrating successful antigen-specific antibody responses in mice.

Area of Science:

  • Vaccinology
  • Molecular Biology
  • Virology

Background:

  • Messenger RNA (mRNA) vaccines are promising alternatives to DNA vaccines due to their safety profile.
  • Key challenges for mRNA vaccines include in vivo instability and limited spread.
  • Bacteriophage MS2 virus-like particles (VLPs) offer high stability, presenting a potential platform for improved RNA vaccines.

Purpose of the Study:

  • To investigate the efficacy of MS2 VLPs as a delivery vector for mRNA vaccines.
  • To assess the in vivo immunogenicity of an MS2 VLP-encapsulated mRNA vaccine in a preclinical model.

Main Methods:

  • Production of MS2 VLPs packaging HIV-1 gag mRNAs in Saccharomyces cerevisiae.
  • Immunization of BALB/c mice with the developed MS2 VLP-mRNA vaccine.
  • Serological analysis to detect antigen-specific antibody responses.

Main Results:

  • Successful production of MS2 VLPs containing mRNA was achieved.
  • Immunization elicited significant antigen-specific antibody responses in mice.
  • The study provides the first in vivo evidence of MS2 VLP-mediated RNA vaccine efficacy.

Conclusions:

  • MS2 VLPs can serve as a stable and effective delivery platform for mRNA vaccines.
  • This phage-based system represents a novel and safe approach for genetic vaccination.
  • Further development of MS2 VLP-based mRNA delivery vectors is warranted.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...